GlassScriptPhysician profile
Dany A Raad
NPI 1659687721
$387,086.44
in general payments reported to CMS, 2019-2025
33 companies · $155K in 2025
The $155K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $238 · 2021: $434 · 2022: $802 · 2023: $94K · 2024: $137K · 2025: $155K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $323K · Travel and Lodging: $42K · Food and Beverage: $12K · Consulting Fee: $6,510 · Honoraria: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $323,189.66 |
| Travel and Lodging | $41,793.99 |
| Food and Beverage | $11,848.79 |
| Consulting Fee | $6,510.00 |
| Honoraria | $1,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $209,296.68 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $123,233.73 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $47,124.68 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $2,805.49 | 2019-2025 | Eohilia, Entyvio, Gattex |
| Abbvie INC. | $1,612.71 | 2019-2025 | |
| Braintree Laboratories, INC. | $522.94 | 2020-2025 | Suflave, Sutab |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $355.51 | 2019-2023 | Xifaxan |
| Pfizer INC. | $274.28 | 2019-2025 | |
| Madrigal Pharmaceuticals | $222.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $209.71 | 2019-2024 | Stelara, Remicade, Simponi Aria |
| Lilly USA, LLC | $190.99 | 2023-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $178.70 | 2021-2022 | |
| Celgene Corporation | $125.49 | 2021-2023 | Zeposia |
| Endogastric Solutions, INC | $112.00 | 2021 | |
| Ferring Pharmaceuticals INC. | $79.32 | 2022-2025 | Rebyota |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $73.51 | 2019 | |
| Aimmune Therapeutics, INC. | $70.11 | 2023-2024 | |
| Celltrion USA INC. | $68.32 | 2025 | Vegzelma |
| Organon LLC | $63.65 | 2024 | |
| Merck Sharp & Dohme LLC | $63.17 | 2023-2024 | Dificid |
| Ethicon US, LLC | $57.85 | 2019 | |
| Ardelyx, INC. | $55.09 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $52.24 | 2023 | Sucraid |
| Ironwood Pharmaceuticals, INC | $43.24 | 2019-2021 | |
| Lucid Diagnostics INC. | $31.80 | 2021-2022 | |
| Redhill Biopharma INC. | $27.41 | 2020-2021 | |
| Shionogi INC | $23.34 | 2019 | |
| Amgen INC. | $22.59 | 2025 | Uplizna |
| Intercept Pharmaceuticals, INC. | $22.52 | 2024 | |
| Integra Lifesciences Corporation | $21.42 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Olympus America INC. | $16.55 | 2020 | |
| Evoke Pharma, INC. | $15.60 | 2023 | Gimoti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.77 | 2024 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dany Raad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.